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Summary Serial determinations of serum alpha-foetoprotein (AFP) concentrations are well established in
monitoring the response to therapy of malignant germ cell tumours. Using a radioimmunoassay (RIA) with a
sensitivity down to 2kuI-1 the majority (57%) of 28 patients with non-AFP producing germ cell tumours had
measurable immunologically-reactive AFP in their serum while on treatment. Follow-up for 11-43 months
(mean 27) without evidence of tumour activity indicated that this immunologically-reactive AFP was unlikely
to be produced by tumour. In patients where the initial serum AFP was raised prior to chemotherapy the
AFP concentration did not fall to the normal range at the end of the treatment in 16 (32%) of 41 patients.
Follow-up of these patients for 9-48 months (mean 27) has resulted in 5 (12%) relapses in this group. Serum
AFP >20kuI1 three months after stopping chemotherapy was a good indicator of residual active tumour
and 4 (57%/) of 7 patients in this group relapsed. The production of detectable serum AFP is probably related
to the type of chemotherapy used and only 7 (14%) of 51 patients treated for gestational choriocarcinoma had
detectable AFP concentrations while on cytotoxic chemotherapy. The problem of interpretation of serum AFP
concentration in patients with malignant germ cell tumour stresses the need to determine whether there are
differences between AFP produced by germ cell tumours and that produced at other sites as a basis for a
sensitive assay system able to discriminate between them.
AFP is a glycoprotein with a molecular weight of
70K daltons. It is produced in several physiological
and disease states and is a normal component of
human foetal serum. It is produced in certain liver
diseases, notably hepatocellular carcinoma
(McIntire et al., 1972) and in situations where there
is hepatic regeneration (Bloomer et al., 1973; Elgort
et al., 1973; Masopust et al., 1968; Waldmann et
al., 1974).
AFP is now used routinely with human chorionic
gonadotrophin (hCG) in the diagnosis of anaplastic
germ cell tumours and in monitoring their response
to therapy and follow-up. The production of AFP
by germ cell tumours is closely associated with the
histological finding of yolk sac or embryonal
elements (N0rgaard-Pedersen et al., 1975; Kurman
et al., 1977; Talerman et al., 1977; Grigor et al.,
1977). A high serum concentration of AFP in the
absence of liver disease or pregnancy is likely to be
due to an anaplastic germ cell tumour or some
other AFP-producing tumour. When present the
serum concentration of AFP correlates well with
the body burden of AFP-producing cells. However,
with more intensive and successful chemotherapy in
the management of patients with metastatic germ
cell tumours, this has raised problems of
interpretation since AFP concentrations above the
normal range may not reflect residual tumour.
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The normal serum concentration of AFP has
been variously quoted as <20ku11 (Javadpour,
1980); usually <16kul1- and always <40kul1-
(Pearson et al., 1979); <30kul-' (Catalona, 1979)
and <20ku 1- (Adinolfi, 1979).
Patients and methods
Radioimmunoassay
Serum AFP was assayed by a conventional liquid
phase, second antibody-precipitated radioimmuno-
assay using a rabbit anti-AFP and sheep anti-rabbit
antibodies. The rabbit anti-AFP was raised against
AFP from foetal cord serum. The normal range of
this assay is considered to be <10kul- and most
assays are sensitive down to 2kul-'. In a group of
2918 subjects the mode was 2ku 1- (64.3%).
Ninety-five percent of these samples had values of
<10kul1- and 99% were <16kul1-. This group
excluded those who were pregnant but a high
proportion were known to have cancers not
producing AFP.
We have reviewed the AFP concentrations in a
group of consecutive patients who had completed
combination chemotherapy for metastatic
malignant germ cell tumours and gestational
trophoblastic tumours. Included in this analysis are
120 patients treated between 1978 and 1982. There
were 69 patients with malignant germ cell tumours
and these included malignant teratomas (testicular,
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ovarian and other primary sites), seminomas and
dysgerminomas. The patients with malignant germ
cell tumours were treated with sequential
combination chemotherapy using cis-platinum,
vincristine, methotrexate, bleomycin, actinomycin
D, cyclophosphamide and etoposide (POMB/ACE)
which has been described previously (Newlands et
al., 1980; 1983). There were 51 patients treated for
gestational trophoblastic tumours. They were
categorised according to established risk factors
(Bagshawe, 1976). Patients who fell into the low
risk category were treated with methotrexate and
folinic acid. Patients in the medium risk category
were treated with sequential therapy including
etoposide followed by hydroxyurea, methotrexate
and 6-mercaptopurine in combination and
actinomycin D. The high risk category were treated
with etoposide, methotrexate, actinomycin D,
alternating with vincristine and cyclophosphamide.
In some cases the high risk patients also received
cis-platinum. The schedules used have been
described in detail (Begent & Bagshawe, 1981;
Newlands & Bagshawe, 1982). While on
chemotherapy all these 120 patients have had twice
weekly serum estimations of AFP and human
chorionic gonadotrophin (hCG).
Results
Since gestational trophoblastic tumours do not
produce AFP, the 51 patients were studied as a
control group of patients on varying intensities of
cytotoxic chemotherapy. The serum AFP
concentrations are shown in Table I. The majority
of cases (86%) did not have detectable AFP in their
serum. However 5 (10%) patients had transient
elevations of alpha-foetoprotein to between 10 and
20kul-1 on chemotherapy and 2 (4%) had a single
serum concentration of 21kul-1. In one of these
patients the elevation of AFP was associated with
marked rise in transaminases and the other patient
had received very extensive chemotherapy over a
number of years for drug-resistant chorio-
carcinoma. These results indicate that even on
intensive chemotherapy it is very unusual (2
estimations out of 790) for the AFP concentration
to be >10kul-' in patients treated with the
chemotherapy schedules used here in gestational
choriocarcinoma.
The patients with malignant germ cell tumours
were divided into 2 groups. In the first there were
28 patients whose initial serum concentration of
alpha-foetoprotein prior to chemotherapy was
<10kul-1. The results in these patients are
summarised in Table II. Sixteen (57%) had an AFP
of >10kuI1 while on POMB/ACE chemotherapy.
Six (21%) had an AFP concentration >20kuI-. In
several patients, as is illustrated in Figure 1 the
serum concentration rose promptly on POMB/ACE
chemotherapy to clearly abnornal levels. However
this immunologically-detectable AFP usually
disappears gradually from the serum over a period
of months after completing chemotherapy, as
shown in Figure 2. In Figure 3 the transient rise in
AFP concentrations correlated with a rise in serum
transaminases. The rise in AFP and in trans-
aminases appeared to be associated with POMB
chemotherapy and may reflect both hepatic damage
and regeneration.
Forty-one patients had initial serum
concentrations of AFP >10ku 1 and their results
are summarised in Table III. Although in the
majority (61%), the AFP concentration at the end
of chemotherapy had fallen to <10ku 11, a
significant proportion (39%) had higher serum
concentrations of AFP. The serum concentration in
many of these patients continued to fluctuate at
concentrations >10kul-1 over the 3 months after
completing therapy. There was a trend for the AFP
concentrations to fall with time and by 3 months
after completing chemotherapy 30 (75%) patients
had serum concentrations of AFP<10ku1-1.
Follow-up of these 69 patients with malignant germ
cell tumours to 1 Feb. 1983 has resulted in 2 (7%)
relapses in the 28 patients with non-AFP-producing
tumours and 5 (12%) relapses out of 41 in patients
with AFP-producing tumours. The serum concen-
Table I AFP estimations in 51 patients treated for gestational trophoblastic tumours
No. ofpatients in each group (%) by Average no. ofestimations
highest AFP concentration (ku 1-') during chemotherapy AFP per patient
Rkeatment Category AFP< 10 AFP 10-20 AFP>20
Low Risk 21 (91) 2 (9) 0 10 (range 3-40)
Medium Risk 14 (88) 1 (6) 1 (6) 11 (range 3-21)
High Risk 9 (75) 2 (17) 1 (8) 31 (range 10-56)
Totals 44 (86) 5 (10) 2 (4) Total AFP estimations=790ALPHA-FOETOPROTEIN: GERM CELL TUMOURS 337
Table II AFP concentrations in 28 patients with non-AFP-producing germ cell tumours
treated with POMB/ACE Chemotherapy
No. ofpatients in each group (%)
by AFP concentration (ku1-1)
AFP< 10 AFP 10-20 AFP>20
Prior to Chemotherapy 28 (100) 0 0
Highest AFP during Chemotherapy 12 (43) 10 (36) 6 (21)
AFP at end ofChemotherapy 25 (89) 2 (7) 1 (3)
Highest during 3 months after
Chemotherapy' 20 (74) 5 (19) 2 (7)
AFP at 3 months after
Chemotherapy' 25 (92)b 1 (4) 1 (4)
'I patient died in a road traffic accident.
'The 2 patients who relapsed in this
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Figure 1 Patient with a Stage IV non-AFP-producing germ cell tumour with undetectable serum AFP prior
to chemotherapy with POMB (cis-platinum, vincristine, methotrexate and bleomycin) and ACE (actinomycin-
D, cyclophosphamide and etoposide) chemotherapy; OMB (vincristine, methotrexate and bleomycin). This
patient's transaminases remained normal throughout his chemotherapy.
tration of AFP at the end of chemotherapy did not Discussion
accurately predict those destined to relapse. The
most important indicator for clinical relapse was a Analysis of these 120 patients has shown that when
progressively rising AFP during the 3 months after measured by RIA the serum AFP had a variable
completing chemotherapy. If the serum AFP was baseline in patients on particular schedules of
>20kul- 3 months after completing treatment cytotoxic chemotherapy. While in many patients
this usually indicated residual tumour and 4 (57%) serial serum samples have AFP concentrations
of these 7 patients relapsed. <2ku -' a number of patients have a fluctuating
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Figure 2 Eighteen-month old boy with metastatic orchioblastoma
POMB/ACE chemotherapy. Although the AFP fell on chemotherapy
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Figure 3 Patient with Stage IV germ cell tumour. The transient rises in AFP appear to be associated with
courses of POMB chemotherapy. The third rise in AFP was associated with transient renal failure (from the
cis-platinum therapy) which necessitated a modification in the sequence ofhis courses ofchemotherapy.
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Table III AFP concentration in 41 patients with AFP-producing germ cell tumours on
POMB/ACE chemotherapy
No. ofpatients in each group (%)
by AFP concentration (ku1 )
AFP< 10 AFP 1-20 AFP>20
Prior to chemotherapy 0 7 (17) 34 (83)
AFP concentration at end of
chemotherapy 25 (61)b 7 (17) 9 (22)
Highest AFP during 3 months
after chemotherapy 15 (38) 11 (27) 14 (35)
(1 patient refused further
blood samples)
AFP at 3 months after
chemotherapy 30 (75) 3 (7) 7 (18)'
(1 patient refused further
blood samples)
aFour of these patients developed a progressive rise in AFP concentrations and
relapsed by other criteria; all have died.
bOne patient relapsed with hCG-producing tumour and is in remission after further
treatment.
background between 2 and 10kul-'. We regard
serum concentrations of AFP between 10 and
20kul-1 as abnormal so long as patients are not
receiving or have not recently received cytotoxic
chemotherapy. The results in the patients with
gestational trophoblastic tumours indicate that a
proportion (10%) of patients can have slight
increases in AFP concentrations on chemotherapy
to between 10 and 20kul-1 but is unusual for
serum concentrations to rise to higher levels on the
chemotherapy that these patients received. This
contrasts with patients with malignant germ cell
tumours receiving POMB/ACE chemotherapy. In
the group where the initial serum concentration of
AFP was <10kul-' as many as 57% of patients
had serum concentrations >10kul-1. In those
patients with rises in serum concentrations of AFP
on chemotherapy, the AFP remained elevated for
some months after completing treatment but there
was usually a progressive fall in AFP with time.
However not all these patients' AFP concentrations
have yet fallen to <10kuI-; with a follow-up time
11-43 months (mean 27) it is unlikely that these
serum concentrations of AFP are detecting tumour-
produced AFP. The most likely interpretation is
that the cytotoxic chemotherapy is stimulating the
production of AFP in other tissues than the
tumour. The source of the AFP detected may be
from hepatic damage and regeneration from the
cytotoxic chemotherapy. This is supported by the
association of the transient rises in AFP with rises
in the serum transaminases (Figure 3). In one
patient whose AFP rose to >300ku 1- after
completing chemotherapy the liver biopsy showed
acute hepatitis compatible with drug-induced
toxicity. This patient's AFP is now falling pro-
gressively towards the normal range.
In patients with initially elevated serum concen-
trations of AFP as many as 39% of 41 patients had
concentrations >10kul- 1' at the time it was
thought reasonable to stop cytotoxic chemotherapy.
Clearly this presents a major problem of
interpretation as to whether the serum AFP is being
produced by residual tumour or by other tissues.
Follow-up of these 16 patients has shown that 4
(25%) have relapsed as indicated by progressively
rising serum concentrations of AFP and clinical or
radiological findings. It therefore seems likely that
in a high proportion of patients with serum
concentrations of AFP>10kul-' treated with
POMB/ACE chemotherapy, this residual immuno-
reactive AFP in the serum is not produced by
tumour. The most frequent pattern of serial AFP
concentrations is that shown in Figure 2. In this
child with metastatic orchioblastoma (histologically
a yolk sac teratoma) the AFP concentration fell on
chemotherapy but did not reach the undetectable
level for a number of months after completing
therapy. In most cases the AFP concentration on
POMB/ACE chemotherapy reached a plateau
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between 10 and 30kul-'. We have used the
criterion of 12 weeks in which AFP concentrations
are in this range before stopping chemotherapy
provided that all other parameters of the disease
are consistent with complete remission. Using these
criteria there have only been 4 relapses in AFP-
producing tumour in this group of 41 patients. All
these 4 patients initially fell into a high-risk group
as defined by an initial serum AFP concentration of
>500kul-1 prior to starting chemotherapy
(Newlands et al., 1983).
These results emphasise the need for a
biochemical test which can discriminate between
tumour-produced AFP and AFP produced by other
tissues in the body. Although the AFP produced by
tumour and other tissues may be immunologically
cross-reactive, it may be possible to separate AFP
produced by different tissues by other means. There
is evidence that AFP occurs as two different
molecular variants which can be separated by their
affinity for concanavalin-A (Smith & Kelleher,
1973). Unfortunately assessment of this method in
our department showed that it is not sensitive
enough to be applied at the concentrations of AFP
which present the clinical problems discussed above
(T. Adams, unpublished observations). Another
possibility is to use radio-crossed immunoelectro-
phoresis which can detect 1 ku -' AFP (Nqrgaard-
Pedersen & Axelsen, 1976). With this method an
AFP-like substance with a gamma mobility has
been identified which is measured by conventional
radioimmunoasgay and can reach concentrations
comparable to those reported here.
We thank all the staff of the Department of Medical
Oncology involved in the clinical care of these patients or
in laboratory measurements and all the surgeons and
radiotherapists who have referred patients to us. We also
thank the Medical Research Council and the Cancer
Research Campaign for support.
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